Rabab joined Earlybird Health in 2020 and is now a Principal, serving as a board member for Grey Wolf Therapeutics, as well as a board observer for ImCheck Therapeutics, Argá Medtech, Priothera, and Prothea Technologies. She has conducted research at renowned institutions, including The George Institute for Global Health, Lowy Cancer Research Centre, Cancer Research UK, and Cambridge University. Rabab holds a PhD in regenerative medicine from UNSW Sydney and the Cancer Research UK Manchester Institute. She also completed a postdoctoral fellowship at the Babraham Institute in Cambridge, specializing in therapeutics for immuno-oncology and autoimmune diseases.